Ignite Creation Date:
2024-07-17 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06489704
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-06-28
Brief Title:
High Altitude HA Residents With High Altitude Pulmonary Hypertension HAPH Pulmonary Artery Pressure PAP Assessed at HA 3200 m vs LA 760 m
Sponsor:
University of Zurich
Organization:
University of Zurich
Study Overview
Official Title:
Comparative Study of Pulmonary Artery Pressure PAP Assessed by Echocardiography in Patients With High Altitude Pulmonary Hypertension HAPH Permanently Residing Above 2500 Meters When Assessed Near Resident High Altitude HA at 3200 m vs at Low Altitude LA at 760 m
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To study the effect of relocation from 3200 m Aksay to 760 m Bishkek in patients with high altitude pulmonary hypertension HAPH who permanently live 2500 m on pulmonary artery pressure PAP
Detailed Description:
This research in highlanders with HAPH diagnosed by echocardiography and defined by a RVRA 30 mmHg who permanently live at HA 2500 m will have pulmonary arterial pressure PAP assessed by echocardiography near their living altitude in Aksay at 3200 m and at 760 m in Bishkek the day after the first and the seventh night after relocation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None